Comments
Loading...
Soleno Therapeutics Analyst Ratings and Price Targets | NASDAQ:SLNO | Benzinga
Soleno Therapeutics Inc has a consensus price target of $101.22 based on the ratings of 9 analysts. The high is $145 issued by Piper Sandler on April 24, 2025. The low is $73 issued by Oppenheimer on October 28, 2024. The 3 most-recent analyst ratings were released by Piper Sandler, HC Wainwright & Co., and HC Wainwright & Co. on April 24, 2025, April 15, 2025, and March 31, 2025, respectively. With an average price target of $115 between Piper Sandler, HC Wainwright & Co., and HC Wainwright & Co., there's an implied 56.06% upside for Soleno Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Piper Sandler
HC Wainwright & Co.
Stifel
Guggenheim
Laidlaw & Co.
1calculated from analyst ratings
Analyst Ratings for Soleno Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/24/2025 | Buy Now | 96.77% | Piper Sandler | Yasmeen Rahimi56% | $93 → $145 | Maintains | Overweight | Get Alert |
| 04/15/2025 | Buy Now | 35.7% | HC Wainwright & Co. | Raghuram Selvaraju42% | $100 → $100 | Reiterates | Buy → Buy | Get Alert |
| 03/31/2025 | Buy Now | 35.7% | HC Wainwright & Co. | Raghuram Selvaraju42% | $70 → $100 | Maintains | Buy | Get Alert |
| 03/28/2025 | Buy Now | 46.56% | Stifel | James Condulis56% | $74 → $108 | Maintains | Buy | Get Alert |
| 03/28/2025 | Buy Now | 9.92% | Guggenheim | Debjit Chattopadhyay51% | $70 → $81 | Maintains | Buy | Get Alert |
| 03/27/2025 | Buy Now | 42.49% | Laidlaw & Co. | Yale Jen22% | $75 → $105 | Maintains | Buy | Get Alert |
| 03/27/2025 | Buy Now | 38.42% | Baird | Brian Skorney57% | $72 → $102 | Maintains | Outperform | Get Alert |
| 03/27/2025 | Buy Now | 66.92% | Cantor Fitzgerald | Kristen Kluska68% | $67 → $123 | Maintains | Overweight | Get Alert |
| 03/05/2025 | Buy Now | 0.42% | Stifel | James Condulis56% | → $74 | Reinstates | → Buy | Get Alert |
| 03/03/2025 | Buy Now | -5.01% | HC Wainwright & Co. | Raghuram Selvaraju42% | $70 → $70 | Reiterates | Buy → Buy | Get Alert |
| 12/02/2024 | Buy Now | -2.29% | Baird | Brian Skorney57% | $72 → $72 | Reiterates | Outperform → Outperform | Get Alert |
| 12/02/2024 | Buy Now | -5.01% | HC Wainwright & Co. | Raghuram Selvaraju42% | $70 → $70 | Reiterates | Buy → Buy | Get Alert |
| 11/11/2024 | Buy Now | -5.01% | HC Wainwright & Co. | Raghuram Selvaraju42% | $70 → $70 | Reiterates | Buy → Buy | Get Alert |
| 10/28/2024 | Buy Now | -0.94% | Oppenheimer | Leland Gershell69% | $65 → $73 | Maintains | Outperform | Get Alert |
| 10/01/2024 | Buy Now | 0.42% | Stifel | Dae Gon Ha47% | $59 → $74 | Maintains | Buy | Get Alert |
| 09/20/2024 | Buy Now | -9.08% | Cantor Fitzgerald | Kristen Kluska68% | $67 → $67 | Reiterates | Overweight → Overweight | Get Alert |
| 09/03/2024 | Buy Now | -5.01% | HC Wainwright & Co. | Raghuram Selvaraju42% | → $70 | Initiates | → Buy | Get Alert |
| 08/12/2024 | Buy Now | -11.79% | Oppenheimer | Leland Gershell69% | $59 → $65 | Maintains | Outperform | Get Alert |
| 07/31/2024 | Buy Now | -9.08% | Cantor Fitzgerald | Kristen Kluska68% | $67 → $67 | Reiterates | Overweight → Overweight | Get Alert |
| 05/13/2024 | Buy Now | -19.93% | Oppenheimer | Leland Gershell69% | $65 → $59 | Maintains | Outperform | Get Alert |
| 05/10/2024 | Buy Now | -2.29% | Baird | Brian Skorney57% | → $72 | Initiates | → Outperform | Get Alert |
| 02/05/2024 | Buy Now | 26.2% | Piper Sandler | Yasmeen Rahimi56% | → $93 | Initiates | → Overweight | Get Alert |
| 01/23/2024 | Buy Now | -14.51% | Stifel | Dae Gon Ha47% | → $63 | Initiates | → Buy | Get Alert |
| 01/02/2024 | Buy Now | -36.22% | Oppenheimer | Leland Gershell69% | $44 → $47 | Maintains | Outperform | Get Alert |
| 11/21/2023 | Buy Now | -45.72% | Guggenheim | Debjit Chattopadhyay51% | → $40 | Assumes | → Buy | Get Alert |
| 09/26/2023 | Buy Now | -52.5% | Cantor Fitzgerald | Kristen Kluska68% | $19 → $35 | Maintains | Overweight | Get Alert |
| 09/15/2023 | Buy Now | -81% | Oppenheimer | Leland Gershell69% | $8 → $14 | Maintains | Outperform | Get Alert |
| 08/31/2023 | Buy Now | -74.22% | Cantor Fitzgerald | Kristen Kluska68% | → $19 | Reiterates | Overweight → Overweight | Get Alert |
| 07/11/2023 | Buy Now | -74.22% | Cantor Fitzgerald | Kristen Kluska68% | → $19 | Initiates | → Overweight | Get Alert |
| 05/25/2023 | Buy Now | -89.14% | Oppenheimer | Leland Gershell69% | → $8 | Reiterates | → Outperform | Get Alert |
| 03/24/2023 | Buy Now | -89.14% | Oppenheimer | Leland Gershell69% | → $8 | Reiterates | → Outperform | Get Alert |
FAQ
What is the target price for Soleno Therapeutics (SLNO) stock?
The latest price target for Soleno Therapeutics (NASDAQ:SLNO) was reported by Piper Sandler on April 24, 2025. The analyst firm set a price target for $145.00 expecting SLNO to rise to within 12 months (a possible 96.77% upside). 21 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Soleno Therapeutics (SLNO)?
The latest analyst rating for Soleno Therapeutics (NASDAQ:SLNO) was provided by Piper Sandler, and Soleno Therapeutics maintained their overweight rating.
When was the last upgrade for Soleno Therapeutics (SLNO)?
There is no last upgrade for Soleno Therapeutics
When was the last downgrade for Soleno Therapeutics (SLNO)?
There is no last downgrade for Soleno Therapeutics.
When is the next analyst rating going to be posted or updated for Soleno Therapeutics (SLNO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Soleno Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Soleno Therapeutics was filed on April 24, 2025 so you should expect the next rating to be made available sometime around April 24, 2026.
Is the Analyst Rating Soleno Therapeutics (SLNO) correct?
While ratings are subjective and will change, the latest Soleno Therapeutics (SLNO) rating was a maintained with a price target of $93.00 to $145.00. The current price Soleno Therapeutics (SLNO) is trading at is $73.69, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
